Metraipolis › archive › dc_ef275ea7dd5d

Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks — Europe PMC PMID:41303215

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41303215
DOI
10.3390/jcm14228181
License (as archived)
solo-consultazione
Archived
2026-11-08T11:48:11.571Z
SHA-256 of the archived text
cb21d671e9bbd93dbd72bf8984a234e6c13e8a40fdfea107f39cbb5f2cc39777
Stable URL of this page
https://metraipolis.com/documento/dc_ef275ea7dd5d

How to cite

Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks — Europe PMC PMID:41303215 — Europe PMC (en), https://europepmc.org/article/MED/41303215 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ef275ea7dd5d (Metraipolis archive dc_ef275ea7dd5d, sha256 cb21d671e9bbd93dbd72bf8984a234e6c13e8a40fdfea107f39cbb5f2cc39777)
BibTeX
@misc{dcef275ea7dd5d,
  title = {Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks — Europe PMC PMID:41303215},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41303215},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ef275ea7dd5d; sha256 cb21d671e9bbd93dbd72bf8984a234e6c13e8a40fdfea107f39cbb5f2cc39777},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41303215. Agents can read the archived copy with the MCP tool read_document.